Cargando…

Epilepsy lifetime prevalence in Iran: a large population- based national survey

Epilepsy has garnered increased public health focus because patients who suffer from epilepsy experience pronounced and persistent health and socioeconomic disparities despite treatment and care advances. The epidemiology of epilepsy is diverse in different countries and regions. This nationwide pop...

Descripción completa

Detalles Bibliográficos
Autores principales: Pakdaman, Hossein, Harandi, Ali Amini, Gharagozli, Koroush, Alaeddini, Farshid, Esfandani, Akram, Mirbehbahani, Seyed Hamidreza, Doroudi, Taher, Kolivand, Pirhossein, Bahrami, Parviz, Kazemi, Hadi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8093423/
https://www.ncbi.nlm.nih.gov/pubmed/33941831
http://dx.doi.org/10.1038/s41598-021-89048-z
_version_ 1783687805759651840
author Pakdaman, Hossein
Harandi, Ali Amini
Gharagozli, Koroush
Alaeddini, Farshid
Esfandani, Akram
Mirbehbahani, Seyed Hamidreza
Doroudi, Taher
Kolivand, Pirhossein
Bahrami, Parviz
Kazemi, Hadi
author_facet Pakdaman, Hossein
Harandi, Ali Amini
Gharagozli, Koroush
Alaeddini, Farshid
Esfandani, Akram
Mirbehbahani, Seyed Hamidreza
Doroudi, Taher
Kolivand, Pirhossein
Bahrami, Parviz
Kazemi, Hadi
author_sort Pakdaman, Hossein
collection PubMed
description Epilepsy has garnered increased public health focus because patients who suffer from epilepsy experience pronounced and persistent health and socioeconomic disparities despite treatment and care advances. The epidemiology of epilepsy is diverse in different countries and regions. This nationwide population-based cross-sectional study was conducted to determine the life time prevalence and health related factors of epilepsy for the first time in Iran through a two-phase door-to-door survey method. In phase I, a screening for epilepsy was performed on 68,035 people. Then in phase II, after the neurological evaluation of participants and reviewing medical records, 1130 subjects with epilepsy was confirmed. The life time prevalence of epilepsy was achieved to be 16.6 per 1000 people (95% CI 15.4–17.8) with the average age onset 19.1 ± 21.1 (active prevalence 9.5 per 1000 people). Focal seizure (59.3%), generalized epilepsy (38%) and unknown types of epilepsy (2.7%) were detected among participants. The overall life time prevalence of febrile convulsion was 4.1 per 1000 people. The frequency of attacks per year and per month were 3.0 ± 1.6 and 0.5 ± 0.1, respectively. Age-specific life time prevalence was highest among the age group of 15–19 years old [32.7 per 1000 persons (95% CI 29.1–36.8)] and it was higher in male (53.8%) than female (46.2%) participants. Our results showed that the life time prevalence of epilepsy in Iran is higher than worldwide average.
format Online
Article
Text
id pubmed-8093423
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-80934232021-05-05 Epilepsy lifetime prevalence in Iran: a large population- based national survey Pakdaman, Hossein Harandi, Ali Amini Gharagozli, Koroush Alaeddini, Farshid Esfandani, Akram Mirbehbahani, Seyed Hamidreza Doroudi, Taher Kolivand, Pirhossein Bahrami, Parviz Kazemi, Hadi Sci Rep Article Epilepsy has garnered increased public health focus because patients who suffer from epilepsy experience pronounced and persistent health and socioeconomic disparities despite treatment and care advances. The epidemiology of epilepsy is diverse in different countries and regions. This nationwide population-based cross-sectional study was conducted to determine the life time prevalence and health related factors of epilepsy for the first time in Iran through a two-phase door-to-door survey method. In phase I, a screening for epilepsy was performed on 68,035 people. Then in phase II, after the neurological evaluation of participants and reviewing medical records, 1130 subjects with epilepsy was confirmed. The life time prevalence of epilepsy was achieved to be 16.6 per 1000 people (95% CI 15.4–17.8) with the average age onset 19.1 ± 21.1 (active prevalence 9.5 per 1000 people). Focal seizure (59.3%), generalized epilepsy (38%) and unknown types of epilepsy (2.7%) were detected among participants. The overall life time prevalence of febrile convulsion was 4.1 per 1000 people. The frequency of attacks per year and per month were 3.0 ± 1.6 and 0.5 ± 0.1, respectively. Age-specific life time prevalence was highest among the age group of 15–19 years old [32.7 per 1000 persons (95% CI 29.1–36.8)] and it was higher in male (53.8%) than female (46.2%) participants. Our results showed that the life time prevalence of epilepsy in Iran is higher than worldwide average. Nature Publishing Group UK 2021-05-03 /pmc/articles/PMC8093423/ /pubmed/33941831 http://dx.doi.org/10.1038/s41598-021-89048-z Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Pakdaman, Hossein
Harandi, Ali Amini
Gharagozli, Koroush
Alaeddini, Farshid
Esfandani, Akram
Mirbehbahani, Seyed Hamidreza
Doroudi, Taher
Kolivand, Pirhossein
Bahrami, Parviz
Kazemi, Hadi
Epilepsy lifetime prevalence in Iran: a large population- based national survey
title Epilepsy lifetime prevalence in Iran: a large population- based national survey
title_full Epilepsy lifetime prevalence in Iran: a large population- based national survey
title_fullStr Epilepsy lifetime prevalence in Iran: a large population- based national survey
title_full_unstemmed Epilepsy lifetime prevalence in Iran: a large population- based national survey
title_short Epilepsy lifetime prevalence in Iran: a large population- based national survey
title_sort epilepsy lifetime prevalence in iran: a large population- based national survey
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8093423/
https://www.ncbi.nlm.nih.gov/pubmed/33941831
http://dx.doi.org/10.1038/s41598-021-89048-z
work_keys_str_mv AT pakdamanhossein epilepsylifetimeprevalenceiniranalargepopulationbasednationalsurvey
AT harandialiamini epilepsylifetimeprevalenceiniranalargepopulationbasednationalsurvey
AT gharagozlikoroush epilepsylifetimeprevalenceiniranalargepopulationbasednationalsurvey
AT alaeddinifarshid epilepsylifetimeprevalenceiniranalargepopulationbasednationalsurvey
AT esfandaniakram epilepsylifetimeprevalenceiniranalargepopulationbasednationalsurvey
AT mirbehbahaniseyedhamidreza epilepsylifetimeprevalenceiniranalargepopulationbasednationalsurvey
AT dorouditaher epilepsylifetimeprevalenceiniranalargepopulationbasednationalsurvey
AT kolivandpirhossein epilepsylifetimeprevalenceiniranalargepopulationbasednationalsurvey
AT bahramiparviz epilepsylifetimeprevalenceiniranalargepopulationbasednationalsurvey
AT kazemihadi epilepsylifetimeprevalenceiniranalargepopulationbasednationalsurvey